Insmed Incorporated (INSM)Healthcare | Biotechnology | Bridgewater, United States | NasdaqGS
109.14 USD
-6.47
(-5.596%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 108.40 -0.74 (-0.740%) ⇩ (July 13, 2026, 7:15 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:23 a.m. EDT
Insmed offers a compelling growth narrative backed by an eight-year price surge exceeding 800% and revenue expansion nearing 230%, yet the absence of profitability and the recent clinical trial setback create substantial uncertainty. The valuation commands a heavy premium relative to sales, relying entirely on future execution rather than current earnings power. While the balance sheet provides a cash buffer, the negative free cash flow means capital is being consumed to fuel expansion. Investors must weigh the analyst consensus of a strong buy against the tangible risks of binary outcomes in drug development. There is no income component to cushion the downside, making this a pure speculation on capital appreciation suitable only for those comfortable with high volatility and potential binary events. |
| Model | MAE |
|---|---|
| MSTL_90 ✓ | 0.225261 |
| MSTL_90_126 | 0.239878 |
| MSTL | 0.297095 |
| AutoETS | 0.302507 |
| AutoARIMA | 0.302508 |
| MSTL_126 | 0.320164 |
| AutoTheta | 0.330933 |
Forecast horizon: 60 days | Selected: MSTL_90
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 2.90 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.086 |
| Excess Kurtosis | -1.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 105.336 |
| Revenue per Share | 3.947 |
| Market Cap | 23,656,361,984 |
| Forward P/E | 579.95 |
| Beta | 0.78 |
| Profit Margins | -144.44% |
| Previous Name | Apeiros |
| Website | https://www.insmed.com |
As of July 11, 2026, 6:23 a.m. EDT: Implied volatility ranges between 60% and 70% across expirations. Open interest is skewed toward out-of-the-money calls for late 2027 and 2028, indicating speculative bets on a significant upside move. Conversely, near-term put activity at the 100 strike suggests hedging or defensive positioning against volatility. Deep out-of-the-money strikes show inflated premiums, reflecting tail risk concerns.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.134655 |
| Address1 | 700 US Highway 202/206 |
| All Time High | 212.75 |
| All Time Low | 2.64 |
| Ask | 117.76 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 3,037,540 |
| Average Daily Volume3 Month | 3,801,077 |
| Average Volume | 3,801,077 |
| Average Volume10Days | 3,037,540 |
| Beta | 0.778 |
| Bid | 99.8 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 3.255 |
| City | Bridgewater |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 109.14 |
| Current Ratio | 4.469 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 115.55 |
| Day Low | 108.02 |
| Debt To Equity | 105.336 |
| Earnings Call Timestamp End | 1,778,155,200 |
| Earnings Call Timestamp Start | 1,778,155,200 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -949,036,032 |
| Ebitda Margins | -1.15798 |
| Enterprise To Ebitda | -24.42 |
| Enterprise To Revenue | 28.278 |
| Enterprise Value | 23,175,311,360 |
| Eps Current Year | -2.64285 |
| Eps Forward | 0.18819 |
| Eps Trailing Twelve Months | -5.44 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 109.108 |
| Fifty Day Average Change | 0.03199768 |
| Fifty Day Average Change Percent | 0.00029326612 |
| Fifty Two Week Change Percent | 13.4655 |
| Fifty Two Week High | 212.75 |
| Fifty Two Week High Change | -103.61 |
| Fifty Two Week High Change Percent | -0.48700354 |
| Fifty Two Week Low | 90.39 |
| Fifty Two Week Low Change | 18.75 |
| Fifty Two Week Low Change Percent | 0.20743445 |
| Fifty Two Week Range | 90.39 - 212.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 959,866,200,000 |
| Float Shares | 198,421,696 |
| Forward Eps | 0.18819 |
| Forward P E | 579.9458 |
| Free Cashflow | -606,202,112 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,664 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.8181 |
| Gross Profits | 670,483,968 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0051700003 |
| Held Percent Institutions | 1.0364499 |
| Implied Shares Outstanding | 216,752,451 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investor.insmed.com/stockquote.cfm |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,299,110,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. |
| Long Name | Insmed Incorporated |
| Market | us_market |
| Market Cap | 23,656,361,984 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_29978 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -1,183,755,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 25,058,750,860 |
| Number Of Analyst Opinions | 21 |
| Open | 114.25 |
| Operating Cashflow | -895,664,000 |
| Operating Margins | -0.65459 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.09 |
| Phone | 908 977 9900 |
| Post Market Change | -0.73999786 |
| Post Market Change Percent | -0.67802626 |
| Post Market Price | 108.4 |
| Post Market Time | 1,783,984,546 |
| Prev Name | Apeiros |
| Previous Close | 115.61 |
| Price Eps Current Year | -41.29633 |
| Price Hint | 2 |
| Price To Book | 33.529953 |
| Price To Sales Trailing12 Months | 28.864569 |
| Profit Margins | -1.4443699 |
| Quick Ratio | 3.884 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22727 |
| Region | US |
| Regular Market Change | -6.47 |
| Regular Market Change Percent | -5.5964 |
| Regular Market Day High | 115.55 |
| Regular Market Day Low | 108.02 |
| Regular Market Day Range | 108.02 - 115.55 |
| Regular Market Open | 114.25 |
| Regular Market Previous Close | 115.61 |
| Regular Market Price | 109.14 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 2,824,267 |
| Return On Assets | -0.31107 |
| Return On Equity | -2.9446201 |
| Revenue Growth | 2.296 |
| Revenue Per Share | 3.947 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 216,752,451 |
| Shares Percent Shares Out | 0.074 |
| Shares Short | 16,030,053 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 19,132,984 |
| Short Name | Insmed Incorporated |
| Short Percent Of Float | 0.0834 |
| Short Ratio | 3.2 |
| Source Interval | 15 |
| State | NJ |
| Symbol | INSM |
| Target High Price | 243.0 |
| Target Low Price | 140.0 |
| Target Mean Price | 196.33333 |
| Target Median Price | 200.0 |
| Total Cash | 1,223,513,984 |
| Total Cash Per Share | 5.645 |
| Total Debt | 742,462,016 |
| Total Revenue | 819,564,032 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 151.0128 |
| Two Hundred Day Average Change | -41.872803 |
| Two Hundred Day Average Change Percent | -0.27727982 |
| Type Disp | Equity |
| Volume | 2,824,267 |
| Website | https://www.insmed.com |
| Zip | 8,807 |